Big pharma’s biggest spenders revealed
Bristol Myers Squibb has spent the most on M&A, R&D and licensing since 2017, and Eli Lilly the least. Guess which strategy is working best.
Opportunities arise for once-spurned partners
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Market crash throws up a rich deal for Cullinan
Trading well below cash hasn’t stopped Cullinan from extracting more from Otsuka, when a low-ball buyout might have been on the cards.
Six months on, Biohaven succumbs to Pfizer
Biohaven looks to have timed its exit well, giving investors more reason to cheer the $11.6bn buyout.
For medtechs seeking deals, it’s hurry up and wait
Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.
